FGFR1 and non-small cell squamous lung carcinoma: Studies have shown that Infigratinib is effective in treating FGFR1-amplified squamous non-small cell lung cancer (sqNSCLC), gliomas with FGFR1 mutations, and urothelial carcinoma with FGFR1 overexpression [66,67,68].